Table 1. Characteristics of 3 patients with THA PJI.

	Case 1	Case 2	Case 3
Age (years)	45	54	75
Sex	Female	Male	Female
Body Weight (kg)	95	82	90
THA Material	Metal-on-polyethylene	Metal-on-polyethylene	Metal-on-polyethylene
THA Fixation	Hybrid	Cemented	Hybrid
Underlying systemic diseases	No	No	No
Symptoms and signs of infection
- Pain	Yes	Yes	Yes
- Erythema	Yes	No	Yes
- Swelling	Yes	Yes	Yes
- Fever (≥38°C)	Yes	Yes	No
- Sinus tract	No	No	No
- Bacteremia	No	No	No
Baseline laboratory data
- C-reactive protein mg/l	121	34	56
- ESR mm/1 hour	70	83	34
Time from implant to infection diagnosis (days)	13	11	7
Time from implant to debridement (days)	14	17	42
Time from infection onset to debridement (days)	4	6	35
Number of surgical samples obtained at first debridement	4	4	7
Number of positive culture / number of surgical samples obtained	4/4	4/4	6/7
Additional debridement required (number)	4	1	1
Intravenous tigecycline therapy
Total Treatment Duration (days)	60	30	30
Inpatient Treatment (days)	28	10	6
Catheter used for drug infusion	CVC	PICC	PICC
Concomitant Drug
Colistin (duration in days)	12	8	6
Oral minocycline (200 mg/day) after tigecycline discontinuation (months)	3	7	No
Follow up after therapy discontinuation (months)	28	31	30

THA, total hip arthroplasty; PJI, prosthetic joint infection; ESR, erythrocyte sedimentation rate;

CVC, central venous catheter; PICC, peripherally inserted central catheter.